<DOC>
	<DOCNO>NCT02209948</DOCNO>
	<brief_summary>The purpose study show prolong treatment temozolomide 12 cycle improve progression-free survival patient glioblastoma include study , randomize accord o6-methylguanine-DNA-methyltransferase ( MGMT ) methylation status residual disease , receive additional 6 cycle temozolomide .</brief_summary>
	<brief_title>Temozolomide 12 Cycles Versus 6 Cycles Standard First-line Treatment Patients With Glioblastoma .</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Ability understand sign inform consent document . 2 . Age great equal 18 . 3 . Patients glioblastoma accord WHO classification ( glioblastoma ) receive chemo radiotherapy temozolomide base chemotherapy ( Stupp scheme ) complete 6 cycle adjuvant temozolomide ( without bevacizumab ) context standard treatment without present progression disease . 4 . Availability tumor tissue first surgery centralized histological review , determine MGMT study do center origin . ( If make center origin result center accept ) . 5 . Stable dose dexamethasone inclusion never corticoid dose receive cycle 6 adjuvant . 6 . Index great equal 60 % Karnofsky . 7 . All patient must show progression disease brain nuclear magnetic resonance ( NMR ) define RANO establish criterion randomization . 8 . Basal NMR study maximum 6 week prior inclusion , progress observe permitted manage care 6th cycle ( NMR perform 6th cycle adjuvant also acceptable long progression observe ) . 9 . Adequate bone marrow reserve : hematocrit great equal 29 % , white blood cell &gt; 3,000 , RAN great equal 1,500 cell / ul , platelet great equal 100,000 cell / ul . 10 . Creatinine &lt; 1.5 time upper limit normal ( ULN ) laboratory perform analysis . 11 . Serum bilirubin &lt; 1.5 / ULN ; SGOT , SGPT &lt; 2.5 time upper limit normal laboratory perform analysis . Serum &lt; 3/ULN alkaline phosphatase . 12 . Effective contraceptive method patient partner . 1 . Less 5 year previous invasive neoplasia . In situ cervical carcinoma basal cell skin carcinoma accept . 2 . Concomitant treatment investigational agent ( concomitant bevacizumab ) . 3 . Presence clinically significant gastrointestinal abnormality may affect decision , transit absorption study drug , inability take medication tablet mouth . 4 . Presence psychiatric cognitive disorder limit understand write informed consent / impair compliance requirement protocol . 5 . Concurrent disease prevents continuation temozolomide treatment . 6 . Presence leptomeningeal dissemination . 7 . Pregnant breastfeeding . 8 . Positive patient receive combination antiretroviral therapy HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>